Skip to main content

Catalyst Calendar

Mon, Aug 10, 2026

1 updates

9:05 AM

BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston

biomarin.com

Thu, Aug 6, 2026

1 updates

4:03 PM

BioMarin Reports Second Quarter 2026 Financial and Operating Results

biomarin.com

Thu, Jul 30, 2026

1 updates

9:00 AM

BioMarin to Host Second Quarter 2026 Financial Results Conference Call and Webcast on Thursday, August 6, 2026, at 4:30pm ET

biomarin.com

Mon, Jul 27, 2026

1 updates

9:05 AM

BioMarin and n-Lorem Foundation Enter Early Research Collaboration to Develop Potential First-in-Disease Medicine for Newly Identified ReNU Syndrome

biomarin.com

Mon, Jul 13, 2026

1 updates

9:05 AM

U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With Achondroplasia

biomarin.com

Tue, Jun 16, 2026

1 updates

9:05 AM

BioMarin Announces New Three-Year VOXZOGO® (vosoritide) Data in Hypochondroplasia and BMN 333 Early Results at ENDO 2026

Presentation / Abstractbiomarin.com

Wed, May 20, 2026

1 updates

4:20 PM

BioMarin Announces Positive Phase 3 Pivotal Study Results for VOXZOGO® (vosoritide) in Children with Hypochondroplasia

Trial Results • Phase 3biomarin.com